BRI3BP is a 27.8 kDa protein encoded on chromosome 12.2-qter that is highly expressed in brain, kidney, and liver tissues 1. As an endoplasmic reticulum (ER)-resident protein, BRI3BP functions in cell fate decisions and apoptosis regulation. When overexpressed, BRI3BP augments drug-induced apoptosis in human cells by enhancing mitochondrial cytochrome c release and caspase-3 activity, while BRI3BP knockdown reduces drug-triggered apoptosis 2. The protein appears to modulate ER structural dynamics in response to cellular stress. In cancer contexts, BRI3BP shows complex roles: elevated expression correlates with hepatocellular carcinoma progression, advanced tumor stage, shorter overall survival, and activation of pro-tumorigenic pathways including ROCK signaling and immunosuppression 3. Similarly, BRI3BP emerges as a prognostic biomarker in gastric cancer risk models 4. However, evidence suggests BRI3BP may negatively regulate p53 function through interactions with HCCR-1, potentially contributing to tumorigenesis by impairing p53-dependent transcription 5. Recent discovery of a de novo missense variant (p.Val160Ile) in a calf with congenital cardiac and skeletal malformations implicates BRI3BP in cardiac and bone development 6, highlighting its broader developmental significance beyond cancer pathways.